Applied Therapeutics' Cash Dwindles Amidst Mounting Losses

TL;DR

**APLT is burning cash fast and facing a 'going concern' warning; steer clear unless you're betting on a miracle financing deal.**

AI Summary

Applied Therapeutics, Inc. reported a net loss of $43.155 million for the six months ended June 30, 2025, a significant improvement from the $81.040 million net loss in the same period of 2024. This improvement was primarily driven by a favorable change in the fair value of warrant liabilities, which contributed $4.541 million in income for the first half of 2025, compared to a $40.660 million expense in the prior year. Revenue from research and development services dropped to $0 for the six months ended June 30, 2025, down from $334 thousand in 2024. Total operating expenses increased to $48.623 million for the first half of 2025, up from $41.867 million in 2024, largely due to a rise in general and administrative expenses to $30.863 million from $19.646 million. The company's cash and cash equivalents decreased significantly to $30.421 million as of June 30, 2025, from $79.398 million at December 31, 2024, with net cash used in operating activities totaling $48.977 million for the six months ended June 30, 2025. Applied Therapeutics also reported an accumulated deficit of $617.365 million as of June 30, 2025, and management has concluded that substantial doubt exists about its ability to continue as a going concern within one year.

Why It Matters

Applied Therapeutics' precarious financial position, highlighted by a significant drop in cash to $30.4 million and an accumulated deficit of $617.4 million, poses a substantial risk to investors. The 'going concern' warning signals potential insolvency, which could lead to significant shareholder dilution or even bankruptcy if new financing isn't secured. For employees, this raises job security concerns, while customers and the broader market face uncertainty regarding the continued development of novel product candidates for rare diseases like Galactosemia and SORD deficiency. In the highly competitive biopharmaceutical landscape, the inability to secure funding could severely hinder the company's ability to advance its pipeline and compete with better-capitalized rivals.

Risk Assessment

Risk Level: high — The company explicitly states that 'substantial doubt' exists about its ability to continue as a going concern within one year, a critical red flag. Cash and cash equivalents plummeted from $79.398 million at December 31, 2024, to $30.421 million by June 30, 2025, representing a 61.7% decrease in six months. Net cash used in operating activities was $48.977 million for the six months ended June 30, 2025, indicating a rapid cash burn.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in Applied Therapeutics, Inc. given the explicit 'going concern' warning and rapid cash depletion. Potential investors should avoid initiating new positions until the company secures substantial long-term financing or a strategic partnership, as the risk of significant capital loss is high.

Financial Highlights

debt To Equity

1.14

revenue

$0

operating Margin

N/A

total Assets

$37.342M

total Debt

$19.904M

net Income

($43.155M)

eps

($0.30)

gross Margin

N/A

cash Position

$30.421M

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $43.155M — Net Loss (6 months) (Improved from $81.040M in prior year, but still significant.)
• $30.421M — Cash & Cash Equivalents (Decreased from $79.398M at year-end 2024, indicating rapid cash burn.)
• $617.365M — Accumulated Deficit (Reflects substantial historical losses and ongoing unprofitability.)
• $48.977M — Net Cash Used in Operating Activities (6 months) (Highlights the company's significant cash burn rate from operations.)
• $0 — Revenue (6 months) (No revenue generated from R&D services, down from $334K in 2024.)
• $4.541M — Change in Fair Value of Warrant Liabilities (6 months) (Positive impact on net income, contrasting with a $40.660M expense in 2024.)
• $48.623M — Total Costs and Expenses (6 months) (Increased from $41.867M in 2024, driven by G&A.)
• 141,938,335 — Shares Outstanding (As of June 30, 2025, indicating potential for further dilution.)

Key Players & Entities

• Applied Therapeutics, Inc. (company) — clinical-stage biopharmaceutical company
• SEC (regulator) — Securities and Exchange Commission
• $43.155 million (dollar_amount) — net loss for six months ended June 30, 2025
• $81.040 million (dollar_amount) — net loss for six months ended June 30, 2024
• $30.421 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $79.398 million (dollar_amount) — cash and cash equivalents as of December 31, 2024
• $617.365 million (dollar_amount) — accumulated deficit as of June 30, 2025
• $48.977 million (dollar_amount) — net cash used in operating activities for six months ended June 30, 2025
• Galactosemia (disease) — rare metabolic disease targeted by the company
• Sorbitol Dehydrogenase (SORD) deficiency (disease) — rare metabolic disease targeted by the company

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management has concluded that substantial doubt exists about Applied Therapeutics, Inc.'s ability to continue as a going concern within one year. This is underscored by a significant decrease in cash and cash equivalents to $30.421 million as of June 30, 2025, from $79.398 million at December 31, 2024, and net cash used in operating activities of $48.977 million for the six months ended June 30, 2025.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $617.365 million as of June 30, 2025. This substantial deficit reflects a history of significant net losses and ongoing unprofitability, raising concerns about long-term financial viability.
• Increased Operating Expenses [medium — financial]: Total operating expenses increased to $48.623 million for the first half of 2025, up from $41.867 million in the prior year. This rise was primarily driven by a significant increase in general and administrative expenses to $30.863 million from $19.646 million.
• Dependence on Financing [high — financial]: The company's continued operations are highly dependent on its ability to secure additional funding. The substantial cash burn rate, evidenced by $48.977 million in net cash used in operating activities for the first six months of 2025, necessitates ongoing access to capital markets or other financing sources.
• Lack of Revenue Generation [medium — operational]: For the six months ended June 30, 2025, the company reported $0 in revenue from research and development services, a complete drop from $334 thousand in the same period of 2024. This indicates a potential challenge in commercializing or monetizing its R&D efforts.
• Warrant Liability Fluctuations [medium — financial]: While the change in fair value of warrant liabilities provided a $4.541 million income benefit in the first half of 2025, it contrasted sharply with a $40.660 million expense in the prior year. Such volatility can impact reported net income and financial stability.
• Shareholder Dilution Potential [medium — financial]: With 141,938,335 shares outstanding as of June 30, 2025, and a history of losses, the company may need to issue additional equity to fund operations, potentially leading to significant dilution for existing shareholders.

Industry Context

Applied Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing treatments for rare diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often hinges on clinical trial outcomes, intellectual property protection, and the ability to secure substantial funding for ongoing research and development.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Applied Therapeutics is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety endpoints, or issues with manufacturing processes can lead to significant setbacks or outright rejection of drug candidates, impacting future revenue and financial stability.

What Investors Should Do

1. Monitor cash runway closely: With cash and cash equivalents at $30.421 million and significant operating cash burn, investors should track the company's ability to secure additional financing to avoid insolvency.
2. Scrutinize R&D pipeline progress: Given the lack of current revenue, the success and timeline of the company's drug development programs are paramount. Investors should look for positive clinical trial data and regulatory milestones.
3. Assess G&A expense control: The substantial increase in general and administrative expenses to $30.863 million warrants close examination to understand cost drivers and potential for efficiency improvements.
4. Evaluate future financing needs: The company's accumulated deficit and going concern warning suggest future equity raises are likely, which could dilute existing shareholders. Investors should consider the potential impact of dilution.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported $30.421M in cash, $617.365M accumulated deficit, and $48.977M net cash used in operations for H1 2025. Management indicated going concern doubt.
• 2024-06-30: End of Q2 2024 — Reported $81.040M net loss for H1 2024, with $334K R&D revenue and a $40.660M expense from warrant liabilities.
• 2024-12-31: End of Fiscal Year 2024 — Company held $79.398M in cash and cash equivalents and had an accumulated deficit of $574.210M.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability, standing at $617.365 million as of June 30, 2025.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (Management's conclusion of substantial doubt about Applied Therapeutics' ability to continue as a going concern is a critical warning sign for investors.)

Fair value of warrant liabilities

The estimated market price of outstanding warrants, which can fluctuate and impact the company's net income. (A significant swing from a $40.660 million expense in H1 2024 to a $4.541 million income in H1 2025 materially affected the reported net loss.)

Net cash used in operating activities

The amount of cash a company has spent on its core business operations over a period. (A high figure of $48.977 million for H1 2025 highlights the company's substantial cash burn rate from its ongoing operations.)

Research and development services revenue

Revenue generated from providing R&D services to third parties. (The complete absence of this revenue ($0) in H1 2025, down from $334 thousand in H1 2024, signals a potential issue with this revenue stream.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Applied Therapeutics has significantly reduced its net loss from $81.040 million to $43.155 million, largely due to a favorable $4.541 million change in warrant liabilities versus a $40.660 million expense. However, this improvement is overshadowed by a complete drop in R&D revenue to $0 from $334 thousand and a substantial increase in total operating expenses to $48.623 million, driven by higher general and administrative costs. The company's cash position has also deteriorated sharply, falling from $79.398 million at year-end 2024 to $30.421 million, reinforcing concerns about its financial stability and ability to continue as a going concern.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 APLT The Nasdaq Global Market Ind

Filing Documents

• aplt-20250630.htm (10-Q) — 2658KB
• aplt-ex31_1.htm (EX-31.1) — 18KB
• aplt-ex31_2.htm (EX-31.2) — 21KB
• aplt-ex32_1.htm (EX-32.1) — 11KB
• aplt-ex32_2.htm (EX-32.2) — 10KB
• 0000950170-25-108172.txt ( ) — 9706KB
• aplt-20250630.xsd (EX-101.SCH) — 1331KB
• aplt-20250630_htm.xml (XML) — 1627KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Balance Sheets 4 Condensed Statements of Operations 5 Condensed Statements of Stockholders' Equity/(Deficit) 6 Condensed Statements of Cash Flows 8 Notes to Condensed Financial Statements (Unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 40 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 94 Item 3. Defaults Upon Senior Securities 94 Item 4. Mine Safety Disclosures 94 Item 5. Other Information 94 Item 6. Exhibits 95

Signatures

Signatures 96 We own various U.S. federal trademarks, including our company name and logo, that we use in connection with the operation of our business. This Quarterly Report on Form 10-Q includes our trademarks and trade names which are protected under applicable intellectual property laws and are our property. This Quarterly Report on Form 10-Q also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report on Form 10-Q may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. From time to time, we may use our website and our X (formerly known as Twitter) account at @Applied_Tx to distribute material information about us and for complying with our disclosure obligations under Regulation FD. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.appliedtherapeutics.com. Investors are encouraged to review the Investors & Media section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website and our X posts are not incorporated into, and does not form a part of, this Quarterly Report on Form 10-Q. 1 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q may contain "forwar

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Applied Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share and per share data) (Unaudited) As of As of June 30, December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 30,421 $ 79,398 Prepaid expenses and other current assets 4,090 4,248 Total current assets 34,511 83,646 Security deposits 252 253 Operating lease right-of-use asset 2,579 2,792 TOTAL ASSETS $ 37,342 $ 86,691 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current portion of operating lease liabilities $ 447 $ 406 Accounts payable 4,861 4,433 Accrued expenses and other current liabilities 10,668 16,143 Warrant liabilities 1,773 6,314 Total current liabilities 17,749 27,296 NONCURRENT LIABILITIES: Noncurrent portion of operating lease liabilities 2,155 2,389 Total noncurrent liabilities 2,155 2,389 Total liabilities 19,904 29,685 STOCKHOLDERS' EQUITY: Common stock, $ 0.0001 par value; 250,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 141,938,335 shares issued and outstanding as of June 30, 2025 and 137,228,741 shares issued and outstanding as of December 31, 2024 35 35 Preferred stock, par value $ 0.0001 ; 10,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Additional paid-in capital 634,768 631,181 Accumulated deficit ( 617,365 ) ( 574,210 ) Total stockholders' equity 17,438 57,006 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 37,342 $ 86,691 The Notes to Condensed Financial Statements are an integral part of these statements. 4 Table of Contents Applied Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share data) (Unaudited) Three Months Ended Six Months Ended June 30, June

View Full Filing

View this 10-Q filing on SEC EDGAR